Lonza Group (OTCMKTS:LZAGY) Rating Lowered to “Strong Sell” at Zacks Research

Lonza Group (OTCMKTS:LZAGY) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Lonza Group Stock Performance

Shares of LZAGY stock opened at $66.36 on Wednesday. Lonza Group has a twelve month low of $55.57 and a twelve month high of $73.85. The stock’s fifty day simple moving average is $68.23 and its 200 day simple moving average is $68.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.87 and a current ratio of 1.46.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.